Telmisartan 80mg+Hydrochlorothiazide (HCTZ) 25 mg in Hypertension: an Observational Study
It is a national, retrospective , observational study in hypertensive patients treated for at least 8 weeks with the fixed dose combination of telmisartan 80 mg and hydrochlorothiazide 25 mg. The primary objective is to assess the control rate (systolic and diastolic blood pressure). Key secondary objectives are to assess the blood pressure reduction after at least 8 weeks of treatment, describe the population treated with this new fixed dose combination
|Study Design:||Observational Model: Cohort
Time Perspective: Retrospective
|Official Title:||A Descriptive Pharmaco-epidemiological Study of a Hypertensive Patient Population Treated With a Fixed-dose Combination of Telmisartan 80 mg and Hydrochlorothiazide 25 mg and of Conditions for the Management of Arterial Hypertension|
- Rate of BP Control in Hypertensive Patients [ Time Frame: Baseline to a minimum of 8 weeks of treatment ] [ Designated as safety issue: No ]
Mean Percentage of controlled Patients at the Study End.
Control rate of hypertension in general practice and in cardiology defined as systolic blood pressure (SBP) and diastolic blood pressure (DBP) <140/90 mmHg for unselected hypertensive patients and SBP and DBP <130/80 mmHg for hypertensive patients at high cardiovascular risk (patients with diabetes and patients with impaired renal function) as defined in the recommendations of the French National Health Authority (HAS) 2005 guidelines.
- Systolic Blood Pressure (SBP) After at Least 8 Weeks of Treatment in Overall Study Population [ Time Frame: baseline to a minimum of 8 weeks of treatment ] [ Designated as safety issue: No ]Mean SBP measured at the Study End
- Diastolic Blood Pressure (DBP) After at Least 8 Weeks of Treatment in Overall Study Population [ Time Frame: baseline to a minimum of 8 weeks of treatment ] [ Designated as safety issue: No ]Mean DBP measured at the Study End
|Study Start Date:||May 2009|
|Primary Completion Date:||November 2009 (Final data collection date for primary outcome measure)|
Show 915 Study Locations
|Study Chair:||Boehringer Ingelheim||Boehringer Ingelheim Pharmaceuticals|